Form 4: Tevogen Bio Holdings Director Receives Stock Grant

Tevogen Bio Holdings Inc. reports a restricted stock grant to Director Curtis L. Patton, with vesting tied to revenue milestones.

Summary

• Director Curtis L. Patton was granted 40,000 shares of common stock in Tevogen Bio Holdings Inc. on July 10, 2026.
• This grant is part of the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The shares vest in three equal installments, contingent on the reporting person remaining in service and the company achieving specific aggregate revenue targets: $50 million, $100 million, and $150 million since the grant date, on the first, second, and third anniversaries of the grant date, respectively.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard compensation grant with performance-based vesting, which is neither inherently positive nor negative without further context on the company's financial performance and outlook.

Positives

• Director receives a stock grant, indicating potential alignment of management interests with shareholder value.
• Vesting is tied to significant revenue milestones ($50M, $100M, $150M), incentivizing growth and performance.

Negatives

• The grant is a non-cash award, and its value is contingent on future performance and stock price appreciation.
• The vesting conditions are substantial and may not be met, meaning the shares may not fully vest.

Risks

• Failure to achieve the specified aggregate revenue targets ($50 million, $100 million, $150 million) will prevent the full vesting of the restricted stock.
• The reporting person's continued service with the Issuer is a condition for vesting on each installment date.
• The value of the stock grant is subject to market fluctuations and the company's overall stock performance.

Future Outlook

The future outlook for the stock grant is dependent on the company achieving significant revenue growth, specifically $50 million, $100 million, and $150 million in aggregate revenue over the next three years, alongside the continued service of Director Curtis L. Patton.

Industry Context

StockSavvy.ai notes that performance-based equity grants tied to revenue targets are a common practice in the biotechnology sector to align executive incentives with growth and commercial success, especially for companies in earlier stages of development or market penetration.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with company growth, potentially benefiting shareholders if revenue targets are met and the stock price increases. However, it also represents potential future dilution if shares vest.
• Employees: The success required for vesting may lead to a more stable and growing company, benefiting employees.
• Management: Director Patton is incentivized to drive revenue growth and remain with the company.

Next Steps

• Monitor Tevogen Bio Holdings Inc.'s revenue growth to assess progress towards vesting milestones.
• Observe the continued service of Director Curtis L. Patton.
• Track the company's stock performance in relation to the potential value of the granted shares.

Key Dates

Keywords

Tevogen Bio Holdings, TVGN, Form 4, Stock Grant, Restricted Stock, Omnibus Incentive Plan, Director Compensation, Vesting Schedule, Revenue Milestones